MX2012007704A - Composiciones nutritivas y metodos para usar las mismas. - Google Patents
Composiciones nutritivas y metodos para usar las mismas.Info
- Publication number
- MX2012007704A MX2012007704A MX2012007704A MX2012007704A MX2012007704A MX 2012007704 A MX2012007704 A MX 2012007704A MX 2012007704 A MX2012007704 A MX 2012007704A MX 2012007704 A MX2012007704 A MX 2012007704A MX 2012007704 A MX2012007704 A MX 2012007704A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- subjects
- malnutrition
- compositions
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000000050 nutritive effect Effects 0.000 title 1
- 208000002720 Malnutrition Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000001071 malnutrition Effects 0.000 abstract 4
- 235000000824 malnutrition Nutrition 0.000 abstract 4
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000000502 dialysis Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 235000016236 parenteral nutrition Nutrition 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 abstract 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 abstract 1
- 208000037848 Metastatic bone disease Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 abstract 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 abstract 1
- 230000000121 hypercalcemic effect Effects 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 229960001319 parathyroid hormone Drugs 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La invención proporciona composiciones de nutrición parenteral intradialítica (IDPN = intradialytic parenteral nutrition) con bajos carbohidratos para el tratamiento de desnutrición en sujetos en diálisis. En algunas modalidades, las composiciones IDPN son ventajosas para el tratamiento de la desnutrición en sujetos diabéticos o que sufren de otras patologías relacionadas a la administración de glucosa o sujetos que se benefician de estricta administración de fluidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29213910P | 2010-01-04 | 2010-01-04 | |
US29280610P | 2010-01-06 | 2010-01-06 | |
PCT/US2010/043944 WO2011081679A1 (en) | 2010-01-04 | 2010-07-30 | Nutritive compositions and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007704A true MX2012007704A (es) | 2013-01-29 |
Family
ID=44226741
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007704A MX2012007704A (es) | 2010-01-04 | 2010-07-30 | Composiciones nutritivas y metodos para usar las mismas. |
MX2012007775A MX2012007775A (es) | 2010-01-04 | 2010-12-15 | Composiciones nutritivas y metodos para utilizar las mismas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007775A MX2012007775A (es) | 2010-01-04 | 2010-12-15 | Composiciones nutritivas y metodos para utilizar las mismas. |
Country Status (13)
Country | Link |
---|---|
US (3) | US8927505B2 (es) |
EP (2) | EP2521559A4 (es) |
JP (3) | JP5774603B2 (es) |
KR (2) | KR20120125487A (es) |
CN (2) | CN102883729A (es) |
AU (2) | AU2010337355A1 (es) |
BR (2) | BR112012016435A2 (es) |
CA (2) | CA2786375A1 (es) |
GB (2) | GB2489163A (es) |
IL (1) | IL220715A0 (es) |
MX (2) | MX2012007704A (es) |
NZ (2) | NZ601027A (es) |
WO (2) | WO2011081679A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053683A2 (en) * | 2005-11-01 | 2007-05-10 | Fresenius Medical Care Holdings, Inc. | Digital data entry methods and devices |
US20100137693A1 (en) * | 2005-11-01 | 2010-06-03 | Fresenius Medical Care Holdings, Inc. | Methods and systems for patient care |
JP5498491B2 (ja) * | 2008-07-07 | 2014-05-21 | ペンテック ヘルス, インコーポレイテッド | 栄養組成物およびその栄養組成物の使用方法 |
US8698741B1 (en) | 2009-01-16 | 2014-04-15 | Fresenius Medical Care Holdings, Inc. | Methods and apparatus for medical device cursor control and touchpad-based navigation |
US10799117B2 (en) * | 2009-11-05 | 2020-10-13 | Fresenius Medical Care Holdings, Inc. | Patient treatment and monitoring systems and methods with cause inferencing |
US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
CN104619348B (zh) * | 2012-11-27 | 2018-05-01 | 泰尔茂株式会社 | 腹膜透析液 |
EP3352586A4 (en) | 2015-09-21 | 2019-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | NUTRITIONAL ANTICANCER TREATMENT |
SE542106C2 (en) * | 2016-08-26 | 2020-02-25 | Atif M Dabdoub | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis |
EP3723772A4 (en) * | 2017-12-11 | 2021-09-08 | Filtricine, Inc. | COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY |
CA3143834A1 (en) * | 2019-07-19 | 2021-01-28 | Xiyan LI | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses |
US11278510B2 (en) | 2019-09-05 | 2022-03-22 | Baxter International Inc. | Parenteral nutrition formulation with optimized amino acid and glucose content |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489097A (en) | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
EP0077354A4 (en) | 1981-04-27 | 1983-09-30 | Baxter Travenol Lab | DIALYSIS SOLUTION CONTAINING GLUCOSE, AMINO ACIDS AND INSULIN. |
US4491589A (en) | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
US4604286A (en) * | 1984-09-17 | 1986-08-05 | Daigo Nutritive Chemicals, Ltd. | Infusion solution for parenteral nutrition |
JPS6178719A (ja) | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
JPH0667831B2 (ja) * | 1986-01-13 | 1994-08-31 | 森永乳業株式会社 | 肝物質合成機能障害改善用のアミノ酸組成物 |
US5122515A (en) | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
US5278149A (en) | 1992-01-17 | 1994-01-11 | New England Deaconess Hospital Corporation | Method of preparing total parenteral nutrition solutions |
US6380163B1 (en) | 1992-12-22 | 2002-04-30 | Baxter International Inc. | Peritoneal dialysis solutions with polypeptides |
US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
JP2990686B2 (ja) | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | 水溶性ビタミンb類配合総合輸液 |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
SE9703775L (sv) | 1997-10-16 | 1999-04-17 | Pharmalink Baslaekemedel Ab | Framställning av sterial lösningar som innehåller glukos |
US6610206B1 (en) | 1998-10-20 | 2003-08-26 | Advanced Renal Technologies | Buffered compositions for dialysis |
US7670491B2 (en) | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
JP2002045420A (ja) | 2000-08-01 | 2002-02-12 | Terumo Corp | 血液浄化装置、血液浄化方法および透析液パッケージ |
CA2437090C (en) | 2001-02-07 | 2010-10-19 | Nephros, Inc. | Method and apparatus for a hemodiafiltration delivery module |
EP1279400A1 (en) | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
US7445801B2 (en) | 2002-06-07 | 2008-11-04 | Baxter International Inc. | Stable bicarbonate-based solution in a single container |
US7323206B1 (en) | 2003-03-04 | 2008-01-29 | B. Braun Medical Inc. | Reagents and methods for all-in-one total parenteral nutrition for neonates and infants |
JP4594232B2 (ja) * | 2003-05-22 | 2010-12-08 | 株式会社大塚製薬工場 | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 |
US20050148647A1 (en) | 2003-10-31 | 2005-07-07 | Landry Donald W. | Hemodialysis solutions and uses thereof |
JP4622311B2 (ja) * | 2004-05-21 | 2011-02-02 | 味の素株式会社 | 末梢静脈投与用輸液 |
JP2007056013A (ja) | 2005-07-29 | 2007-03-08 | Ajinomoto Co Inc | 透析用補充液 |
PT1909736E (pt) * | 2005-08-02 | 2014-12-23 | Baxter Int | Indicador de oxigénio para utilização em produtos médicos e pacote contendo um indicador de oxigénio |
JP2007137836A (ja) | 2005-11-21 | 2007-06-07 | Ajinomoto Co Inc | 末梢静脈栄養輸液 |
DE102006018293A1 (de) | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
JP5316918B2 (ja) | 2006-04-24 | 2013-10-16 | 味の素株式会社 | 透析患者用輸液剤 |
CN101015501B (zh) * | 2007-02-28 | 2012-03-07 | 华瑞制药有限公司 | 三腔袋包装的脂肪乳、氨基酸和葡萄糖注射液的组合物及其制备方法 |
WO2008146732A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液 |
JP5498491B2 (ja) | 2008-07-07 | 2014-05-21 | ペンテック ヘルス, インコーポレイテッド | 栄養組成物およびその栄養組成物の使用方法 |
WO2010055963A1 (en) | 2008-11-17 | 2010-05-20 | Lee, Jin Tae | Manufacturing method of acetate-free dialysate composition |
-
2010
- 2010-07-30 NZ NZ601027A patent/NZ601027A/en unknown
- 2010-07-30 BR BR112012016435A patent/BR112012016435A2/pt not_active IP Right Cessation
- 2010-07-30 CN CN2010800647187A patent/CN102883729A/zh active Pending
- 2010-07-30 WO PCT/US2010/043944 patent/WO2011081679A1/en active Application Filing
- 2010-07-30 GB GB1211987.1A patent/GB2489163A/en not_active Withdrawn
- 2010-07-30 MX MX2012007704A patent/MX2012007704A/es not_active Application Discontinuation
- 2010-07-30 KR KR1020127020543A patent/KR20120125487A/ko not_active Application Discontinuation
- 2010-07-30 JP JP2012547991A patent/JP5774603B2/ja active Active
- 2010-07-30 AU AU2010337355A patent/AU2010337355A1/en not_active Abandoned
- 2010-07-30 EP EP10841409.5A patent/EP2521559A4/en not_active Withdrawn
- 2010-07-30 US US12/847,513 patent/US8927505B2/en active Active
- 2010-07-30 CA CA2786375A patent/CA2786375A1/en not_active Abandoned
- 2010-12-15 MX MX2012007775A patent/MX2012007775A/es unknown
- 2010-12-15 BR BRBR112012016434-1A patent/BR112012016434A2/pt not_active IP Right Cessation
- 2010-12-15 KR KR1020127020550A patent/KR20120104417A/ko not_active Application Discontinuation
- 2010-12-15 CN CN2010800647242A patent/CN102883603A/zh active Pending
- 2010-12-15 JP JP2012547986A patent/JP2013516463A/ja active Pending
- 2010-12-15 NZ NZ601043A patent/NZ601043A/en unknown
- 2010-12-15 WO PCT/US2010/003192 patent/WO2011081660A1/en active Application Filing
- 2010-12-15 EP EP10841395.6A patent/EP2521449A4/en not_active Withdrawn
- 2010-12-15 AU AU2010337336A patent/AU2010337336A1/en not_active Abandoned
- 2010-12-15 CA CA2786122A patent/CA2786122A1/en not_active Abandoned
- 2010-12-15 GB GB1211991.3A patent/GB2491279A/en not_active Withdrawn
-
2012
- 2012-07-01 IL IL220715A patent/IL220715A0/en unknown
- 2012-07-03 US US13/541,604 patent/US20120277170A1/en not_active Abandoned
-
2014
- 2014-11-25 US US14/552,725 patent/US20150080323A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094645A patent/JP2015187112A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2011081660A1 (en) | 2011-07-07 |
CN102883729A (zh) | 2013-01-16 |
KR20120104417A (ko) | 2012-09-20 |
MX2012007775A (es) | 2013-02-21 |
CA2786122A1 (en) | 2011-07-11 |
US8927505B2 (en) | 2015-01-06 |
CA2786375A1 (en) | 2011-07-07 |
KR20120125487A (ko) | 2012-11-15 |
JP2015187112A (ja) | 2015-10-29 |
IL220715A0 (en) | 2012-08-30 |
CN102883603A (zh) | 2013-01-16 |
EP2521559A1 (en) | 2012-11-14 |
WO2011081679A1 (en) | 2011-07-07 |
JP5774603B2 (ja) | 2015-09-09 |
GB201211987D0 (en) | 2012-08-22 |
GB2489163A (en) | 2012-09-19 |
EP2521559A4 (en) | 2013-05-01 |
AU2010337336A1 (en) | 2012-07-26 |
US20100317602A1 (en) | 2010-12-16 |
AU2010337355A1 (en) | 2012-07-26 |
US20120277170A1 (en) | 2012-11-01 |
JP2013516463A (ja) | 2013-05-13 |
JP2013516464A (ja) | 2013-05-13 |
GB2491279A (en) | 2012-11-28 |
GB201211991D0 (en) | 2012-08-22 |
NZ601043A (en) | 2014-10-31 |
NZ601027A (en) | 2014-08-29 |
BR112012016435A2 (pt) | 2019-09-24 |
BR112012016434A2 (pt) | 2015-09-01 |
US20150080323A1 (en) | 2015-03-19 |
EP2521449A4 (en) | 2013-04-24 |
EP2521449A1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007704A (es) | Composiciones nutritivas y metodos para usar las mismas. | |
CY1121922T1 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
NZ700805A (en) | Devices and methods for additive manufacturing of implant components | |
MX355063B (es) | Calcimiméticos y métodos para su uso. | |
MX2020003901A (es) | Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento. | |
WO2010053548A3 (en) | Pthr1 receptor compounds | |
MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
JOP20200325A1 (ar) | تركيبات وطرق لمعالجة الاعتلالات الهيموجلوبينية والثلاسيمية | |
TN2010000125A1 (en) | Substituted biphenyl gpr40 modulators | |
EA200700273A1 (ru) | Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана | |
MX346717B (es) | Dispositivos de recogida de sangre que contienen un agente estabilizador de sangre. | |
EP3730614A3 (en) | Modulators of growth hormone receptor | |
NZ599833A (en) | Method of preventing type 1 diabetes | |
AU2017367699A8 (en) | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation | |
MX2022003969A (es) | Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. | |
EP4157324A4 (en) | PTH ANALOGUES FOR TREATING HYPOPARATHYROSIS | |
MX2009006476A (es) | Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget. | |
MX2010001584A (es) | Tratamiento o prevencion de infeccion por rotavirus. | |
WO2003094933A3 (en) | Use of lanthanum for the treatment of hypercalcemia and bone metastasis | |
WO2014022665A1 (en) | Subtalar joint prosthesis and installation device | |
BR112017021485A2 (pt) | oligonucleotídeo antissentido isolado, composição farmacêutica, métodos para induzir salto de éxon de um rna de sarcoglicano gama, para aliviar distrofia muscular de cinturas tipo 2c, para inibir a progressão de patologia distrófica associada a lgmd2c e para aprimorar função muscular, e, kit. | |
WO2006033912A3 (en) | Treatment of bone disorders with skeletal anabolic drugs | |
Rachmiel et al. | Reconstruction of the alveolar ridge by osteodistraction for implant placement | |
Avci | Ibandronic acid | |
TR201907941T4 (tr) | Paratiroid hormon seviyelerinin azaltılmasına yönelik terapötik ajanlar. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |